Thursday, 14 Nov 2019

You are here

Testosterone Therapy Yields No Cardiovascular Harm

Are the benefits of androgen supplementation in older men overstated? Might the risks be understated?

In a recent JAMA report, Bashin and colleagues randomly assigned 308 men 60 years or older with low or low-normal testosterone levels to receive testosterone (n = 156) or placebo (n = 152) gel packets daily for 3 years. The dose was adjusted to achieve testosterone levels between 500 and 900 ng/dL. 

Cardiovascular outcomes were assessed by changes in common carotid artery intima-media thickness or coronary artery calcium scores (as measures of subclinical atherosclerosis progression). Scores did not differ significantly between the testosterone or placebo groups. Changes in intima-media thickness or calcium scores were not associated with change in testosterone levels among individuals assigned to receive testosterone.

Additionally, sexual desire, erectile function, overall sexual function scores, partner intimacy, and health-related quality of life did not differ significantly between groups. Hematocrit (a measure of red blood cells) and prostate-specific antigen levels increased more in testosterone group.

Testosterone therapy is neither as good, nor as bad, as it has been reported to be.

Add new comment

More Like This

Rise in Fatty Liver Disease Linked to Obesity and Diabetes

Gut has published population results from NHANES population study showing that the prevalence of fatty liver disease is rising in the US and is driven by obesity and diabetes.

Employed Physicians Outnumber Self-Employed

For the first time in the United States, employed physicians outnumber self-employed physicians, according to a newly updated study on physician practice arrangements by the American Medical Association (AMA). This milestone marks the continuation of a long-term trend that has slowly shifted the distribution of physicians away from ownership of private practices.

 

Dr. Harold E. Paulus (1929-2019)

Dr. Harold “Hal” Paulus lives in the annals of Rheumatology as a major contributor, mentor, researcher and clinical trialist. He passed away last week, one day after his 89th birthday. I met Dr. Paulus as a fellow in 1985, when he easily included me in his discussions and research on rheumatoid arthritis. I admired his easy demeanor, wry humor and every man character. Most remark on his calm recessive and kind personality that was complemented by a body of work that was large, impactful and usually at the cutting edge. Many of Dr. Paulus’ colleagues and friends have contributed their testimonies and fond memories of this great man.

RheumNowLive On Demand: The History of Steroids - Dr. Eric Matteson

A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.

Mourning the Loss of NIAMS Director Stephen Katz, MD, PhD

The following tribute to the late Dr. Steven Katz appeared on the NIH website.